Global Urological Cancer Therapeutics Drugs Market Insights and Forecast to 2028

Publisher Name :
Date: 03-Feb-2022
No. of pages: 116
Inquire Before Buying

Urological Cancer Therapeutics Drugs market is segmented by Type and by Application. Players, stakeholders, and other participants in the global Urological Cancer Therapeutics Drugs market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on sales, revenue and forecast by Type and by Application for the period 2017-2028.

Segment by Type

- Xofigo (radium Ra 223 dichloride)

- Jevtana (cabazitaxel)

- Inlyta (axitinib)

- Votrient (pazopanib hydrochloride)

- Sutent (sunitinib malate)

- Zytiga (abiraterone acetate)

- Xtandi (enzalutamide)

- Opdivo (nivolumab)

- Provenge (sipuleucel-T)

Segment by Application

- Hospital

- Medical Research Laboratory

- Others

By Company

- Novartis

- Pfizer

- Johnson & Johnson

- AstraZeneca

- Astellas

- Bristol-Myers Squibb

- Abbott Laboratories

- Celgene Corporation

- Dendreon Corporation

- Ferring Pharmaceuticals

- GlaxoSmithKline plc

- Indevus Pharmaceuticals Inc

- Ipsen

- Roche Healthcare

- Sanofi S.A.

By Region

- North America

- - U.S.

- - Canada

- Europe

- - Germany

- - France

- - U.K.

- - Italy

- - Russia

- Asia-Pacific

- - China

- - Japan

- - South Korea

- - India

- - Australia

- - China Taiwan

- - Indonesia

- - Thailand

- - Malaysia

- Latin America

- - Mexico

- - Brazil

- - Argentina

- Middle East & Africa

- - Turkey

- - Saudi Arabia

- - UAE

Global Urological Cancer Therapeutics Drugs Market Insights and Forecast to 2028

Table of Contents
1 Study Coverage
1.1 Urological Cancer Therapeutics Drugs Product Introduction
1.2 Market by Type
1.2.1 Global Urological Cancer Therapeutics Drugs Market Size Growth Rate by Type, 2017 VS 2021 VS 2028
1.2.2 Xofigo (radium Ra 223 dichloride)
1.2.3 Jevtana (cabazitaxel)
1.2.4 Inlyta (axitinib)
1.2.5 Votrient (pazopanib hydrochloride)
1.2.6 Sutent (sunitinib malate)
1.2.7 Zytiga (abiraterone acetate)
1.2.8 Xtandi (enzalutamide)
1.2.9 Opdivo (nivolumab)
1.2.10 Provenge (sipuleucel-T)
1.3 Market by Application
1.3.1 Global Urological Cancer Therapeutics Drugs Market Size Growth Rate by Application, 2017 VS 2021 VS 2028
1.3.2 Hospital
1.3.3 Medical Research Laboratory
1.3.4 Others
1.4 Study Objectives
1.5 Years Considered
2 Executive Summary
2.1 Global Urological Cancer Therapeutics Drugs Sales Estimates and Forecasts 2017-2028
2.2 Global Urological Cancer Therapeutics Drugs Revenue Estimates and Forecasts 2017-2028
2.3 Global Urological Cancer Therapeutics Drugs Revenue by Region: 2017 VS 2021 VS 2028
2.4 Global Urological Cancer Therapeutics Drugs Sales by Region
2.4.1 Global Urological Cancer Therapeutics Drugs Sales by Region (2017-2022)
2.4.2 Global Sales Urological Cancer Therapeutics Drugs by Region (2023-2028)
2.5 Global Urological Cancer Therapeutics Drugs Revenue by Region
2.5.1 Global Urological Cancer Therapeutics Drugs Revenue by Region (2017-2022)
2.5.2 Global Urological Cancer Therapeutics Drugs Revenue by Region (2023-2028)
2.6 North America
2.7 Europe
2.8 Asia-Pacific
2.9 Latin America
2.10 Middle East & Africa
3 Competition by Manufacturers
3.1 Global Urological Cancer Therapeutics Drugs Sales by Manufacturers
3.1.1 Global Top Urological Cancer Therapeutics Drugs Manufacturers by Sales (2017-2022)
3.1.2 Global Urological Cancer Therapeutics Drugs Sales Market Share by Manufacturers (2017-2022)
3.1.3 Global Top 10 and Top 5 Largest Manufacturers of Urological Cancer Therapeutics Drugs in 2021
3.2 Global Urological Cancer Therapeutics Drugs Revenue by Manufacturers
3.2.1 Global Urological Cancer Therapeutics Drugs Revenue by Manufacturers (2017-2022)
3.2.2 Global Urological Cancer Therapeutics Drugs Revenue Market Share by Manufacturers (2017-2022)
3.2.3 Global Top 10 and Top 5 Companies by Urological Cancer Therapeutics Drugs Revenue in 2021
3.3 Global Urological Cancer Therapeutics Drugs Sales Price by Manufacturers (2017-2022)
3.4 Analysis of Competitive Landscape
3.4.1 Manufacturers Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Urological Cancer Therapeutics Drugs Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.4.3 Global Urological Cancer Therapeutics Drugs Manufacturers Geographical Distribution
3.5 Mergers & Acquisitions, Expansion Plans
4 Market Size by Type
4.1 Global Urological Cancer Therapeutics Drugs Sales by Type
4.1.1 Global Urological Cancer Therapeutics Drugs Historical Sales by Type (2017-2022)
4.1.2 Global Urological Cancer Therapeutics Drugs Forecasted Sales by Type (2023-2028)
4.1.3 Global Urological Cancer Therapeutics Drugs Sales Market Share by Type (2017-2028)
4.2 Global Urological Cancer Therapeutics Drugs Revenue by Type
4.2.1 Global Urological Cancer Therapeutics Drugs Historical Revenue by Type (2017-2022)
4.2.2 Global Urological Cancer Therapeutics Drugs Forecasted Revenue by Type (2023-2028)
4.2.3 Global Urological Cancer Therapeutics Drugs Revenue Market Share by Type (2017-2028)
4.3 Global Urological Cancer Therapeutics Drugs Price by Type
4.3.1 Global Urological Cancer Therapeutics Drugs Price by Type (2017-2022)
4.3.2 Global Urological Cancer Therapeutics Drugs Price Forecast by Type (2023-2028)
5 Market Size by Application
5.1 Global Urological Cancer Therapeutics Drugs Sales by Application
5.1.1 Global Urological Cancer Therapeutics Drugs Historical Sales by Application (2017-2022)
5.1.2 Global Urological Cancer Therapeutics Drugs Forecasted Sales by Application (2023-2028)
5.1.3 Global Urological Cancer Therapeutics Drugs Sales Market Share by Application (2017-2028)
5.2 Global Urological Cancer Therapeutics Drugs Revenue by Application
5.2.1 Global Urological Cancer Therapeutics Drugs Historical Revenue by Application (2017-2022)
5.2.2 Global Urological Cancer Therapeutics Drugs Forecasted Revenue by Application (2023-2028)
5.2.3 Global Urological Cancer Therapeutics Drugs Revenue Market Share by Application (2017-2028)
5.3 Global Urological Cancer Therapeutics Drugs Price by Application
5.3.1 Global Urological Cancer Therapeutics Drugs Price by Application (2017-2022)
5.3.2 Global Urological Cancer Therapeutics Drugs Price Forecast by Application (2023-2028)
6 North America
6.1 North America Urological Cancer Therapeutics Drugs Market Size by Type
6.1.1 North America Urological Cancer Therapeutics Drugs Sales by Type (2017-2028)
6.1.2 North America Urological Cancer Therapeutics Drugs Revenue by Type (2017-2028)
6.2 North America Urological Cancer Therapeutics Drugs Market Size by Application
6.2.1 North America Urological Cancer Therapeutics Drugs Sales by Application (2017-2028)
6.2.2 North America Urological Cancer Therapeutics Drugs Revenue by Application (2017-2028)
6.3 North America Urological Cancer Therapeutics Drugs Market Size by Country
6.3.1 North America Urological Cancer Therapeutics Drugs Sales by Country (2017-2028)
6.3.2 North America Urological Cancer Therapeutics Drugs Revenue by Country (2017-2028)
6.3.3 U.S.
6.3.4 Canada
7 Europe
7.1 Europe Urological Cancer Therapeutics Drugs Market Size by Type
7.1.1 Europe Urological Cancer Therapeutics Drugs Sales by Type (2017-2028)
7.1.2 Europe Urological Cancer Therapeutics Drugs Revenue by Type (2017-2028)
7.2 Europe Urological Cancer Therapeutics Drugs Market Size by Application
7.2.1 Europe Urological Cancer Therapeutics Drugs Sales by Application (2017-2028)
7.2.2 Europe Urological Cancer Therapeutics Drugs Revenue by Application (2017-2028)
7.3 Europe Urological Cancer Therapeutics Drugs Market Size by Country
7.3.1 Europe Urological Cancer Therapeutics Drugs Sales by Country (2017-2028)
7.3.2 Europe Urological Cancer Therapeutics Drugs Revenue by Country (2017-2028)
7.3.3 Germany
7.3.4 France
7.3.5 U.K.
7.3.6 Italy
7.3.7 Russia
8 Asia Pacific
8.1 Asia Pacific Urological Cancer Therapeutics Drugs Market Size by Type
8.1.1 Asia Pacific Urological Cancer Therapeutics Drugs Sales by Type (2017-2028)
8.1.2 Asia Pacific Urological Cancer Therapeutics Drugs Revenue by Type (2017-2028)
8.2 Asia Pacific Urological Cancer Therapeutics Drugs Market Size by Application
8.2.1 Asia Pacific Urological Cancer Therapeutics Drugs Sales by Application (2017-2028)
8.2.2 Asia Pacific Urological Cancer Therapeutics Drugs Revenue by Application (2017-2028)
8.3 Asia Pacific Urological Cancer Therapeutics Drugs Market Size by Region
8.3.1 Asia Pacific Urological Cancer Therapeutics Drugs Sales by Region (2017-2028)
8.3.2 Asia Pacific Urological Cancer Therapeutics Drugs Revenue by Region (2017-2028)
8.3.3 China
8.3.4 Japan
8.3.5 South Korea
8.3.6 India
8.3.7 Australia
8.3.8 China Taiwan
8.3.9 Indonesia
8.3.10 Thailand
8.3.11 Malaysia
9 Latin America
9.1 Latin America Urological Cancer Therapeutics Drugs Market Size by Type
9.1.1 Latin America Urological Cancer Therapeutics Drugs Sales by Type (2017-2028)
9.1.2 Latin America Urological Cancer Therapeutics Drugs Revenue by Type (2017-2028)
9.2 Latin America Urological Cancer Therapeutics Drugs Market Size by Application
9.2.1 Latin America Urological Cancer Therapeutics Drugs Sales by Application (2017-2028)
9.2.2 Latin America Urological Cancer Therapeutics Drugs Revenue by Application (2017-2028)
9.3 Latin America Urological Cancer Therapeutics Drugs Market Size by Country
9.3.1 Latin America Urological Cancer Therapeutics Drugs Sales by Country (2017-2028)
9.3.2 Latin America Urological Cancer Therapeutics Drugs Revenue by Country (2017-2028)
9.3.3 Mexico
9.3.4 Brazil
9.3.5 Argentina
10 Middle East and Africa
10.1 Middle East and Africa Urological Cancer Therapeutics Drugs Market Size by Type
10.1.1 Middle East and Africa Urological Cancer Therapeutics Drugs Sales by Type (2017-2028)
10.1.2 Middle East and Africa Urological Cancer Therapeutics Drugs Revenue by Type (2017-2028)
10.2 Middle East and Africa Urological Cancer Therapeutics Drugs Market Size by Application
10.2.1 Middle East and Africa Urological Cancer Therapeutics Drugs Sales by Application (2017-2028)
10.2.2 Middle East and Africa Urological Cancer Therapeutics Drugs Revenue by Application (2017-2028)
10.3 Middle East and Africa Urological Cancer Therapeutics Drugs Market Size by Country
10.3.1 Middle East and Africa Urological Cancer Therapeutics Drugs Sales by Country (2017-2028)
10.3.2 Middle East and Africa Urological Cancer Therapeutics Drugs Revenue by Country (2017-2028)
10.3.3 Turkey
10.3.4 Saudi Arabia
11 Company Profiles
11.1 Novartis
11.1.1 Novartis Corporation Information
11.1.2 Novartis Overview
11.1.3 Novartis Urological Cancer Therapeutics Drugs Sales, Price, Revenue and Gross Margin (2017-2022)
11.1.4 Novartis Urological Cancer Therapeutics Drugs Product Model Numbers, Pictures, Descriptions and Specifications
11.1.5 Novartis Recent Developments
11.2 Pfizer
11.2.1 Pfizer Corporation Information
11.2.2 Pfizer Overview
11.2.3 Pfizer Urological Cancer Therapeutics Drugs Sales, Price, Revenue and Gross Margin (2017-2022)
11.2.4 Pfizer Urological Cancer Therapeutics Drugs Product Model Numbers, Pictures, Descriptions and Specifications
11.2.5 Pfizer Recent Developments
11.3 Johnson & Johnson
11.3.1 Johnson & Johnson Corporation Information
11.3.2 Johnson & Johnson Overview
11.3.3 Johnson & Johnson Urological Cancer Therapeutics Drugs Sales, Price, Revenue and Gross Margin (2017-2022)
11.3.4 Johnson & Johnson Urological Cancer Therapeutics Drugs Product Model Numbers, Pictures, Descriptions and Specifications
11.3.5 Johnson & Johnson Recent Developments
11.4 AstraZeneca
11.4.1 AstraZeneca Corporation Information
11.4.2 AstraZeneca Overview
11.4.3 AstraZeneca Urological Cancer Therapeutics Drugs Sales, Price, Revenue and Gross Margin (2017-2022)
11.4.4 AstraZeneca Urological Cancer Therapeutics Drugs Product Model Numbers, Pictures, Descriptions and Specifications
11.4.5 AstraZeneca Recent Developments
11.5 Astellas
11.5.1 Astellas Corporation Information
11.5.2 Astellas Overview
11.5.3 Astellas Urological Cancer Therapeutics Drugs Sales, Price, Revenue and Gross Margin (2017-2022)
11.5.4 Astellas Urological Cancer Therapeutics Drugs Product Model Numbers, Pictures, Descriptions and Specifications
11.5.5 Astellas Recent Developments
11.6 Bristol-Myers Squibb
11.6.1 Bristol-Myers Squibb Corporation Information
11.6.2 Bristol-Myers Squibb Overview
11.6.3 Bristol-Myers Squibb Urological Cancer Therapeutics Drugs Sales, Price, Revenue and Gross Margin (2017-2022)
11.6.4 Bristol-Myers Squibb Urological Cancer Therapeutics Drugs Product Model Numbers, Pictures, Descriptions and Specifications
11.6.5 Bristol-Myers Squibb Recent Developments
11.7 Abbott Laboratories
11.7.1 Abbott Laboratories Corporation Information
11.7.2 Abbott Laboratories Overview
11.7.3 Abbott Laboratories Urological Cancer Therapeutics Drugs Sales, Price, Revenue and Gross Margin (2017-2022)
11.7.4 Abbott Laboratories Urological Cancer Therapeutics Drugs Product Model Numbers, Pictures, Descriptions and Specifications
11.7.5 Abbott Laboratories Recent Developments
11.8 Celgene Corporation
11.8.1 Celgene Corporation Corporation Information
11.8.2 Celgene Corporation Overview
11.8.3 Celgene Corporation Urological Cancer Therapeutics Drugs Sales, Price, Revenue and Gross Margin (2017-2022)
11.8.4 Celgene Corporation Urological Cancer Therapeutics Drugs Product Model Numbers, Pictures, Descriptions and Specifications
11.8.5 Celgene Corporation Recent Developments
11.9 Dendreon Corporation
11.9.1 Dendreon Corporation Corporation Information
11.9.2 Dendreon Corporation Overview
11.9.3 Dendreon Corporation Urological Cancer Therapeutics Drugs Sales, Price, Revenue and Gross Margin (2017-2022)
11.9.4 Dendreon Corporation Urological Cancer Therapeutics Drugs Product Model Numbers, Pictures, Descriptions and Specifications
11.9.5 Dendreon Corporation Recent Developments
11.10 Ferring Pharmaceuticals
11.10.1 Ferring Pharmaceuticals Corporation Information
11.10.2 Ferring Pharmaceuticals Overview
11.10.3 Ferring Pharmaceuticals Urological Cancer Therapeutics Drugs Sales, Price, Revenue and Gross Margin (2017-2022)
11.10.4 Ferring Pharmaceuticals Urological Cancer Therapeutics Drugs Product Model Numbers, Pictures, Descriptions and Specifications
11.10.5 Ferring Pharmaceuticals Recent Developments
11.11 GlaxoSmithKline plc
11.11.1 GlaxoSmithKline plc Corporation Information
11.11.2 GlaxoSmithKline plc Overview
11.11.3 GlaxoSmithKline plc Urological Cancer Therapeutics Drugs Sales, Price, Revenue and Gross Margin (2017-2022)
11.11.4 GlaxoSmithKline plc Urological Cancer Therapeutics Drugs Product Model Numbers, Pictures, Descriptions and Specifications
11.11.5 GlaxoSmithKline plc Recent Developments
11.12 Indevus Pharmaceuticals Inc
11.12.1 Indevus Pharmaceuticals Inc Corporation Information
11.12.2 Indevus Pharmaceuticals Inc Overview
11.12.3 Indevus Pharmaceuticals Inc Urological Cancer Therapeutics Drugs Sales, Price, Revenue and Gross Margin (2017-2022)
11.12.4 Indevus Pharmaceuticals Inc Urological Cancer Therapeutics Drugs Product Model Numbers, Pictures, Descriptions and Specifications
11.12.5 Indevus Pharmaceuticals Inc Recent Developments
11.13 Ipsen
11.13.1 Ipsen Corporation Information
11.13.2 Ipsen Overview
11.13.3 Ipsen Urological Cancer Therapeutics Drugs Sales, Price, Revenue and Gross Margin (2017-2022)
11.13.4 Ipsen Urological Cancer Therapeutics Drugs Product Model Numbers, Pictures, Descriptions and Specifications
11.13.5 Ipsen Recent Developments
11.14 Roche Healthcare
11.14.1 Roche Healthcare Corporation Information
11.14.2 Roche Healthcare Overview
11.14.3 Roche Healthcare Urological Cancer Therapeutics Drugs Sales, Price, Revenue and Gross Margin (2017-2022)
11.14.4 Roche Healthcare Urological Cancer Therapeutics Drugs Product Model Numbers, Pictures, Descriptions and Specifications
11.14.5 Roche Healthcare Recent Developments
11.15 Sanofi S.A.
11.15.1 Sanofi S.A. Corporation Information
11.15.2 Sanofi S.A. Overview
11.15.3 Sanofi S.A. Urological Cancer Therapeutics Drugs Sales, Price, Revenue and Gross Margin (2017-2022)
11.15.4 Sanofi S.A. Urological Cancer Therapeutics Drugs Product Model Numbers, Pictures, Descriptions and Specifications
11.15.5 Sanofi S.A. Recent Developments
12 Industry Chain and Sales Channels Analysis
12.1 Urological Cancer Therapeutics Drugs Industry Chain Analysis
12.2 Urological Cancer Therapeutics Drugs Key Raw Materials
12.2.1 Key Raw Materials
12.2.2 Raw Materials Key Suppliers
12.3 Urological Cancer Therapeutics Drugs Production Mode & Process
12.4 Urological Cancer Therapeutics Drugs Sales and Marketing
12.4.1 Urological Cancer Therapeutics Drugs Sales Channels
12.4.2 Urological Cancer Therapeutics Drugs Distributors
12.5 Urological Cancer Therapeutics Drugs Customers
13 Market Drivers, Opportunities, Challenges and Risks Factors Analysis
13.1 Urological Cancer Therapeutics Drugs Industry Trends
13.2 Urological Cancer Therapeutics Drugs Market Drivers
13.3 Urological Cancer Therapeutics Drugs Market Challenges
13.4 Urological Cancer Therapeutics Drugs Market Restraints
14 Key Findings in The Global Urological Cancer Therapeutics Drugs Study
15 Appendix
15.1 Research Methodology
15.1.1 Methodology/Research Approach
15.1.2 Data Source
15.2 Author Details
15.3 Disclaimer
List of Tables
Table 1. Global Urological Cancer Therapeutics Drugs Market Size Growth Rate by Type, 2017 VS 2021 VS 2028 (US$ Million)
Table 2. Major Manufacturers of Xofigo (radium Ra 223 dichloride)
Table 3. Major Manufacturers of Jevtana (cabazitaxel)
Table 4. Major Manufacturers of Inlyta (axitinib)
Table 5. Major Manufacturers of Votrient (pazopanib hydrochloride)
Table 6. Major Manufacturers of Sutent (sunitinib malate)
Table 7. Major Manufacturers of Zytiga (abiraterone acetate)
Table 8. Major Manufacturers of Xtandi (enzalutamide)
Table 9. Major Manufacturers of Opdivo (nivolumab)
Table 10. Major Manufacturers of Provenge (sipuleucel-T)
Table 11. Global Urological Cancer Therapeutics Drugs Market Size Growth Rate by Application, 2017 VS 2021 VS 2028 (US$ Million)
Table 12. Global Urological Cancer Therapeutics Drugs Revenue by Region: 2017 VS 2021 VS 2028 (US$ Million)
Table 13. Global Urological Cancer Therapeutics Drugs Sales by Region (2017-2022) & (K MT)
Table 14. Global Urological Cancer Therapeutics Drugs Sales Market Share by Region (2017-2022)
Table 15. Global Urological Cancer Therapeutics Drugs Sales by Region (2023-2028) & (K MT)
Table 16. Global Urological Cancer Therapeutics Drugs Sales Market Share by Region (2023-2028)
Table 17. Global Urological Cancer Therapeutics Drugs Revenue by Region (2017-2022) & (US$ Million)
Table 18. Global Urological Cancer Therapeutics Drugs Revenue Market Share by Region (2017-2022)
Table 19. Global Urological Cancer Therapeutics Drugs Revenue by Region (2023-2028) & (US$ Million)
Table 20. Global Urological Cancer Therapeutics Drugs Revenue Market Share by Region (2023-2028)
Table 21. Global Urological Cancer Therapeutics Drugs Sales by Manufacturers (2017-2022) & (K MT)
Table 22. Global Urological Cancer Therapeutics Drugs Sales Share by Manufacturers (2017-2022)
Table 23. Global Urological Cancer Therapeutics Drugs Revenue by Manufacturers (2017-2022) & (US$ Million)
Table 24. Global Urological Cancer Therapeutics Drugs Revenue Share by Manufacturers (2017-2022)
Table 25. Urological Cancer Therapeutics Drugs Price by Manufacturers (2017-2022) &(USD/MT)
Table 26. Global Urological Cancer Therapeutics Drugs Manufacturers Market Concentration Ratio (CR5 and HHI)
Table 27. Global Urological Cancer Therapeutics Drugs by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Urological Cancer Therapeutics Drugs as of 2021)
Table 28. Urological Cancer Therapeutics Drugs Manufacturing Base Distribution and Headquarters
Table 29. Manufacturers Urological Cancer Therapeutics Drugs Product Offered
Table 30. Date of Manufacturers Enter into Urological Cancer Therapeutics Drugs Market
Table 31. Mergers & Acquisitions, Expansion Plans
Table 32. Global Urological Cancer Therapeutics Drugs Sales by Type (2017-2022) & (K MT)
Table 33. Global Urological Cancer Therapeutics Drugs Sales by Type (2023-2028) & (K MT)
Table 34. Global Urological Cancer Therapeutics Drugs Sales Share by Type (2017-2022)
Table 35. Global Urological Cancer Therapeutics Drugs Sales Share by Type (2023-2028)
Table 36. Global Urological Cancer Therapeutics Drugs Revenue by Type (2017-2022) & (US$ Million)
Table 37. Global Urological Cancer Therapeutics Drugs Revenue by Type (2023-2028) & (US$ Million)
Table 38. Global Urological Cancer Therapeutics Drugs Revenue Share by Type (2017-2022)
Table 39. Global Urological Cancer Therapeutics Drugs Revenue Share by Type (2023-2028)
Table 40. Urological Cancer Therapeutics Drugs Price by Type (2017-2022) & (USD/MT)
Table 41. Global Urological Cancer Therapeutics Drugs Price Forecast by Type (2023-2028) & (USD/MT)
Table 42. Global Urological Cancer Therapeutics Drugs Sales by Application (2017-2022) & (K MT)
Table 43. Global Urological Cancer Therapeutics Drugs Sales by Application (2023-2028) & (K MT)
Table 44. Global Urological Cancer Therapeutics Drugs Sales Share by Application (2017-2022)
Table 45. Global Urological Cancer Therapeutics Drugs Sales Share by Application (2023-2028)
Table 46. Global Urological Cancer Therapeutics Drugs Revenue by Application (2017-2022) & (US$ Million)
Table 47. Global Urological Cancer Therapeutics Drugs Revenue by Application (2023-2028) & (US$ Million)
Table 48. Global Urological Cancer Therapeutics Drugs Revenue Share by Application (2017-2022)
Table 49. Global Urological Cancer Therapeutics Drugs Revenue Share by Application (2023-2028)
Table 50. Urological Cancer Therapeutics Drugs Price by Application (2017-2022) & (USD/MT)
Table 51. Global Urological Cancer Therapeutics Drugs Price Forecast by Application (2023-2028) & (USD/MT)
Table 52. North America Urological Cancer Therapeutics Drugs Sales by Type (2017-2022) & (K MT)
Table 53. North America Urological Cancer Therapeutics Drugs Sales by Type (2023-2028) & (K MT)
Table 54. North America Urological Cancer Therapeutics Drugs Revenue by Type (2017-2022) & (US$ Million)
Table 55. North America Urological Cancer Therapeutics Drugs Revenue by Type (2023-2028) & (US$ Million)
Table 56. North America Urological Cancer Therapeutics Drugs Sales by Application (2017-2022) & (K MT)
Table 57. North America Urological Cancer Therapeutics Drugs Sales by Application (2023-2028) & (K MT)
Table 58. North America Urological Cancer Therapeutics Drugs Revenue by Application (2017-2022) & (US$ Million)
Table 59. North America Urological Cancer Therapeutics Drugs Revenue by Application (2023-2028) & (US$ Million)
Table 60. North America Urological Cancer Therapeutics Drugs Sales by Country (2017-2022) & (K MT)
Table 61. North America Urological Cancer Therapeutics Drugs Sales by Country (2023-2028) & (K MT)
Table 62. North America Urological Cancer Therapeutics Drugs Revenue by Country (2017-2022) & (US$ Million)
Table 63. North America Urological Cancer Therapeutics Drugs Revenue by Country (2023-2028) & (US$ Million)
Table 64. Europe Urological Cancer Therapeutics Drugs Sales by Type (2017-2022) & (K MT)
Table 65. Europe Urological Cancer Therapeutics Drugs Sales by Type (2023-2028) & (K MT)
Table 66. Europe Urological Cancer Therapeutics Drugs Revenue by Type (2017-2022) & (US$ Million)
Table 67. Europe Urological Cancer Therapeutics Drugs Revenue by Type (2023-2028) & (US$ Million)
Table 68. Europe Urological Cancer Therapeutics Drugs Sales by Application (2017-2022) & (K MT)
Table 69. Europe Urological Cancer Therapeutics Drugs Sales by Application (2023-2028) & (K MT)
Table 70. Europe Urological Cancer Therapeutics Drugs Revenue by Application (2017-2022) & (US$ Million)
Table 71. Europe Urological Cancer Therapeutics Drugs Revenue by Application (2023-2028) & (US$ Million)
Table 72. Europe Urological Cancer Therapeutics Drugs Sales by Country (2017-2022) & (K MT)
Table 73. Europe Urological Cancer Therapeutics Drugs Sales by Country (2023-2028) & (K MT)
Table 74. Europe Urological Cancer Therapeutics Drugs Revenue by Country (2017-2022) & (US$ Million)
Table 75. Europe Urological Cancer Therapeutics Drugs Revenue by Country (2023-2028) & (US$ Million)
Table 76. Asia Pacific Urological Cancer Therapeutics Drugs Sales by Type (2017-2022) & (K MT)
Table 77. Asia Pacific Urological Cancer Therapeutics Drugs Sales by Type (2023-2028) & (K MT)
Table 78. Asia Pacific Urological Cancer Therapeutics Drugs Revenue by Type (2017-2022) & (US$ Million)
Table 79. Asia Pacific Urological Cancer Therapeutics Drugs Revenue by Type (2023-2028) & (US$ Million)
Table 80. Asia Pacific Urological Cancer Therapeutics Drugs Sales by Application (2017-2022) & (K MT)
Table 81. Asia Pacific Urological Cancer Therapeutics Drugs Sales by Application (2023-2028) & (K MT)
Table 82. Asia Pacific Urological Cancer Therapeutics Drugs Revenue by Application (2017-2022) & (US$ Million)
Table 83. Asia Pacific Urological Cancer Therapeutics Drugs Revenue by Application (2023-2028) & (US$ Million)
Table 84. Asia Pacific Urological Cancer Therapeutics Drugs Sales by Region (2017-2022) & (K MT)
Table 85. Asia Pacific Urological Cancer Therapeutics Drugs Sales by Region (2023-2028) & (K MT)
Table 86. Asia Pacific Urological Cancer Therapeutics Drugs Revenue by Region (2017-2022) & (US$ Million)
Table 87. Asia Pacific Urological Cancer Therapeutics Drugs Revenue by Region (2023-2028) & (US$ Million)
Table 88. Latin America Urological Cancer Therapeutics Drugs Sales by Type (2017-2022) & (K MT)
Table 89. Latin America Urological Cancer Therapeutics Drugs Sales by Type (2023-2028) & (K MT)
Table 90. Latin America Urological Cancer Therapeutics Drugs Revenue by Type (2017-2022) & (US$ Million)
Table 91. Latin America Urological Cancer Therapeutics Drugs Revenue by Type (2023-2028) & (US$ Million)
Table 92. Latin America Urological Cancer Therapeutics Drugs Sales by Application (2017-2022) & (K MT)
Table 93. Latin America Urological Cancer Therapeutics Drugs Sales by Application (2023-2028) & (K MT)
Table 94. Latin America Urological Cancer Therapeutics Drugs Revenue by Application (2017-2022) & (US$ Million)
Table 95. Latin America Urological Cancer Therapeutics Drugs Revenue by Application (2023-2028) & (US$ Million)
Table 96. Latin America Urological Cancer Therapeutics Drugs Sales by Country (2017-2022) & (K MT)
Table 97. Latin America Urological Cancer Therapeutics Drugs Sales by Country (2023-2028) & (K MT)
Table 98. Latin America Urological Cancer Therapeutics Drugs Revenue by Country (2017-2022) & (US$ Million)
Table 99. Latin America Urological Cancer Therapeutics Drugs Revenue by Country (2023-2028) & (US$ Million)
Table 100. Middle East and Africa Urological Cancer Therapeutics Drugs Sales by Type (2017-2022) & (K MT)
Table 101. Middle East and Africa Urological Cancer Therapeutics Drugs Sales by Type (2023-2028) & (K MT)
Table 102. Middle East and Africa Urological Cancer Therapeutics Drugs Revenue by Type (2017-2022) & (US$ Million)
Table 103. Middle East and Africa Urological Cancer Therapeutics Drugs Revenue by Type (2023-2028) & (US$ Million)
Table 104. Middle East and Africa Urological Cancer Therapeutics Drugs Sales by Application (2017-2022) & (K MT)
Table 105. Middle East and Africa Urological Cancer Therapeutics Drugs Sales by Application (2023-2028) & (K MT)
Table 106. Middle East and Africa Urological Cancer Therapeutics Drugs Revenue by Application (2017-2022) & (US$ Million)
Table 107. Middle East and Africa Urological Cancer Therapeutics Drugs Revenue by Application (2023-2028) & (US$ Million)
Table 108. Middle East and Africa Urological Cancer Therapeutics Drugs Sales by Country (2017-2022) & (K MT)
Table 109. Middle East and Africa Urological Cancer Therapeutics Drugs Sales by Country (2023-2028) & (K MT)
Table 110. Middle East and Africa Urological Cancer Therapeutics Drugs Revenue by Country (2017-2022) & (US$ Million)
Table 111. Middle East and Africa Urological Cancer Therapeutics Drugs Revenue by Country (2023-2028) & (US$ Million)
Table 112. Novartis Corporation Information
Table 113. Novartis Description and Major Businesses
Table 114. Novartis Urological Cancer Therapeutics Drugs Sales (K MT), Revenue (US$ Million), Price (USD/MT) and Gross Margin (2017-2022)
Table 115. Novartis Urological Cancer Therapeutics Drugs Product Model Numbers, Pictures, Descriptions and Specifications
Table 116. Novartis Recent Developments
Table 117. Pfizer Corporation Information
Table 118. Pfizer Description and Major Businesses
Table 119. Pfizer Urological Cancer Therapeutics Drugs Sales (K MT), Revenue (US$ Million), Price (USD/MT) and Gross Margin (2017-2022)
Table 120. Pfizer Urological Cancer Therapeutics Drugs Product Model Numbers, Pictures, Descriptions and Specifications
Table 121. Pfizer Recent Developments
Table 122. Johnson & Johnson Corporation Information
Table 123. Johnson & Johnson Description and Major Businesses
Table 124. Johnson & Johnson Urological Cancer Therapeutics Drugs Sales (K MT), Revenue (US$ Million), Price (USD/MT) and Gross Margin (2017-2022)
Table 125. Johnson & Johnson Urological Cancer Therapeutics Drugs Product Model Numbers, Pictures, Descriptions and Specifications
Table 126. Johnson & Johnson Recent Developments
Table 127. AstraZeneca Corporation Information
Table 128. AstraZeneca Description and Major Businesses
Table 129. AstraZeneca Urological Cancer Therapeutics Drugs Sales (K MT), Revenue (US$ Million), Price (USD/MT) and Gross Margin (2017-2022)
Table 130. AstraZeneca Urological Cancer Therapeutics Drugs Product Model Numbers, Pictures, Descriptions and Specifications
Table 131. AstraZeneca Recent Developments
Table 132. Astellas Corporation Information
Table 133. Astellas Description and Major Businesses
Table 134. Astellas Urological Cancer Therapeutics Drugs Sales (K MT), Revenue (US$ Million), Price (USD/MT) and Gross Margin (2017-2022)
Table 135. Astellas Urological Cancer Therapeutics Drugs Product Model Numbers, Pictures, Descriptions and Specifications
Table 136. Astellas Recent Developments
Table 137. Bristol-Myers Squibb Corporation Information
Table 138. Bristol-Myers Squibb Description and Major Businesses
Table 139. Bristol-Myers Squibb Urological Cancer Therapeutics Drugs Sales (K MT), Revenue (US$ Million), Price (USD/MT) and Gross Margin (2017-2022)
Table 140. Bristol-Myers Squibb Urological Cancer Therapeutics Drugs Product Model Numbers, Pictures, Descriptions and Specifications
Table 141. Bristol-Myers Squibb Recent Developments
Table 142. Abbott Laboratories Corporation Information
Table 143. Abbott Laboratories Description and Major Businesses
Table 144. Abbott Laboratories Urological Cancer Therapeutics Drugs Sales (K MT), Revenue (US$ Million), Price (USD/MT) and Gross Margin (2017-2022)
Table 145. Abbott Laboratories Urological Cancer Therapeutics Drugs Product Model Numbers, Pictures, Descriptions and Specifications
Table 146. Abbott Laboratories Recent Developments
Table 147. Celgene Corporation Corporation Information
Table 148. Celgene Corporation Description and Major Businesses
Table 149. Celgene Corporation Urological Cancer Therapeutics Drugs Sales (K MT), Revenue (US$ Million), Price (USD/MT) and Gross Margin (2017-2022)
Table 150. Celgene Corporation Urological Cancer Therapeutics Drugs Product Model Numbers, Pictures, Descriptions and Specifications
Table 151. Celgene Corporation Recent Developments
Table 152. Dendreon Corporation Corporation Information
Table 153. Dendreon Corporation Description and Major Businesses
Table 154. Dendreon Corporation Urological Canc
  • Global Antioxidant Vitamins Market Research Report 2024
    Published: 10-Jan-2024        Price: US 2900 Onwards        Pages: 100
    The global Antioxidant Vitamins market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during The forecast period 2024-2030. North American market for Antioxidant Vitamins is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during The forecast period of 2024 through 2030. Asia-Pacific market for Antioxidant Vitamins is estimated to increase from $ million in 2023 to reach $ millio......
  • Global Clavulanate Potassium Market Research Report 2024
    Published: 10-Jan-2024        Price: US 2900 Onwards        Pages: 86
    The global Clavulanate Potassium market was valued at US$ 446.6 million in 2023 and is anticipated to reach US$ 637.2 million by 2030, witnessing a CAGR of 5.2% during The forecast period 2024-2030. North American market for Clavulanate Potassium is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during The forecast period of 2024 through 2030. Asia-Pacific market for Clavulanate Potassium is estimated to increase from $ million in 2023......
  • Global Amoxicillin Sodium Market Research Report 2024
    Published: 10-Jan-2024        Price: US 2900 Onwards        Pages: 84
    The global Amoxicillin Sodium market was valued at US$ 460.9 million in 2023 and is anticipated to reach US$ 735.1 million by 2030, witnessing a CAGR of 7.0% during The forecast period 2024-2030. North American market for Amoxicillin Sodium is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during The forecast period of 2024 through 2030. Asia-Pacific market for Amoxicillin Sodium is estimated to increase from $ million in 2023 to reach......
  • Global Melatonin Supplements Market Research Report 2024
    Published: 10-Jan-2024        Price: US 2900 Onwards        Pages: 106
    The global Melatonin Supplements market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during The forecast period 2024-2030. North American market for Melatonin Supplements is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during The forecast period of 2024 through 2030. Asia-Pacific market for Melatonin Supplements is estimated to increase from $ million in 2023 to reach $ mil......
  • Global Sleeping Pills (Prescription Drugs) Market Research Report 2024
    Published: 10-Jan-2024        Price: US 2900 Onwards        Pages: 93
    The global Sleeping Pills (Prescription Drugs) market was valued at US$ 1022.3 million in 2023 and is anticipated to reach US$ 1437.8 million by 2030, witnessing a CAGR of 4.9% during The forecast period 2024-2030. The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during The next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, The chemical......
  • Global Sleeping Pills Market Research Report 2024
    Published: 10-Jan-2024        Price: US 2900 Onwards        Pages: 94
    The global Sleeping Pills market was valued at US$ 2042.3 million in 2023 and is anticipated to reach US$ 2979.5 million by 2030, witnessing a CAGR of 3.8% during The forecast period 2024-2030. The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during The next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, The chemical drug market is estim......
  • Global Zinc Oral Drops Market Research Report 2024
    Published: 10-Jan-2024        Price: US 2900 Onwards        Pages: 85
    The global Zinc Oral Drops market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during The forecast period 2024-2030. North American market for Zinc Oral Drops is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during The forecast period of 2024 through 2030. Asia-Pacific market for Zinc Oral Drops is estimated to increase from $ million in 2023 to reach $ million by 2030, at a......
  • Global Zinc Drops Market Research Report 2024
    Published: 10-Jan-2024        Price: US 2900 Onwards        Pages: 85
    The global Zinc Drops market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during The forecast period 2024-2030. North American market for Zinc Drops is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during The forecast period of 2024 through 2030. Asia-Pacific market for Zinc Drops is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % duri......
  • Global Anti-Infectives Market Research Report 2024
    Published: 10-Jan-2024        Price: US 2900 Onwards        Pages: 78
    The global Anti-Infectives market was valued at US$ 22700 million in 2023 and is anticipated to reach US$ 27480 million by 2030, witnessing a CAGR of 2.3% during The forecast period 2024-2030. The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during The next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, The chemical drug market is estima......
  • SERVICES
    Value for Money
    We believe in "optimum utilization of available budget and resources". While servicing our clients' (your) market research requirements, we keep the same approach in focus to help you get the best value for your $$s.
    Ever Growing Inventory
    Ranging from the smallest feasible / required data (datasheets, data facts, SWOT analysis, company profiles, etc) to full research reports that help you make decisions, our inventory is updated almost on a daily basis with the latest industry reports from domain experts that track more than 5000 niche sectors.
    One Stop Solution
    Need a custom research report on medical devices market? Require all available business intelligence on 3D printing industry? Exploring F&B sector of a particular country/region? RnRMarketResearch.com is your one-stop-solution to all market intelligence needs. We not only offer custom research and consulting services, we also "bundle" reports to meet your needs and help you fetch the data analysis you require for your business.
    Dedicated Client Engagement
    Not limited to only "finding" relevant reports for you, our client engagement team dedicates its efforts to understand your "business need" and accordingly maps available research data to help you move forward. Call "your" client engagement executive any time of your day and get your questions answered in order to make the correct business decision.
    Saving Time and Efforts
    Simply share your research requirement details with us and let us do all the hard work to find required intelligence for you. When you add up our "one stop solution" and "dedicated client engagement" services mentioned above, you obviously know the time and effort saving you do by working with us.
    Payment Flexibility
    Working with Fortune 500 organizations, we understand the importance of being flexible for payments. Share your payment terms with us and we will surely match up to them to ensure you get access to required business intelligence data without having to wait for the payment to be done.
    Post-Purchase Research Support
    Have questions after reading a report / datasheet bought through us? Not sure about the methodology used for data available in the research? Talk to us / Share your questions with us and if required, we will connect you with the analyst(s)/author(s) of the report(s) and ensure you get satisfactory answers for the same. Need more data / analysis / report(s) on the topic of your research/project? The RnRMarketResearch.com team is here for you 24X7 to support you with your post-purchase requirements. Subscription Offers & Packages (Get in touch with us for more details - [email protected] / +1 888 391 5441 )
    • Ad Hoc
    • Pay - as - you - go / Bucket Subscriptions
    • Fixed Cost for #of reports
    • Customize / Personalize as per your needs